Tech Company Financing Transactions
Entrada Therapeutics Funding Round
Entrada Therapeutics secured a $116 million Series B investment round on 4/1/2021. Backers included Wellington Management Company, 5AM Ventures and Agent Capital.
Transaction Overview
Company Name
Announced On
4/1/2021
Transaction Type
Venture Equity
Amount
$116,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6 Tide St.
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Entrada Therapeutics' mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada's technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dipal Doshi
Chief Financial Officer
Kory Wentworth
Chief Medical Officer
Nerissa Kreher
Chief Operating Officer
Nathan Dowden
Chief Scientific Officer
Natarajan Sethuraman
VP - General Counsel
Jared Cohen
VP - Human Resources
Kerry Robert
Browse more venture capital transactions:
Prev: 4/1/2021: STORD venture capital transaction
Next: 4/1/2021: UnitedMasters venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs